Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 4169 | 402741-13-3 |
Dose | Unit | Route |
---|---|---|
1.20 | g | P |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 0.53 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 83.60 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.80 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.09 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 29, 2010 | FDA | CEREXA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Off label use | 55.92 | 51.72 | 42 | 405 | 674420 | 62814155 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Off label use | 77.93 | 36.40 | 61 | 551 | 419463 | 34536856 |
Eosinophilia | 48.75 | 36.40 | 18 | 594 | 26204 | 34930115 |
Treatment failure | 38.71 | 36.40 | 18 | 594 | 46679 | 34909640 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Off label use | 69.06 | 38.82 | 61 | 694 | 907154 | 78836479 |
Neutropenia | 63.04 | 38.82 | 37 | 718 | 287673 | 79455960 |
Eosinophilia | 61.40 | 38.82 | 21 | 734 | 45324 | 79698309 |
None
Source | Code | Description |
---|---|---|
ATC | J01DI02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Other cephalosporins and penems |
FDA CS | M0003827 | Cephalosporins |
FDA EPC | N0000175488 | Cephalosporin Antibacterial |
CHEBI has role | CHEBI:33281 | antibiotics |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:50266 | Prodrugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pneumonia due to Escherichia coli | indication | 51530003 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Infection due to Escherichia coli | indication | 71057007 | |
Rhinoscleroma | indication | 72409005 | DOID:11336 |
Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
Pneumococcal pneumonia | indication | 233607000 | |
Streptococcus pyogenes infection | indication | 302809008 | |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Pneumonia due to Staphylococcus aureus | indication | 441658007 | |
Skin and Skin Structure Streptococcus Agalactiae Infection | indication | ||
Hemolytic anemia | contraindication | 61261009 | DOID:583 |
Impaired renal function disorder | contraindication | 197663003 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.48 | acidic |
pKa2 | 2.96 | acidic |
pKa3 | 7.53 | acidic |
pKa4 | 13.05 | acidic |
pKa5 | 2.0 | Basic |
pKa6 | 0.14 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
400MG/VIAL | TEFLARO | ABBVIE | N200327 | Oct. 29, 2010 | RX | POWDER | INTRAVENOUS | 8247400 | Feb. 10, 2031 | METHOD OF TREATING BACTERIAL INFECTIONS |
600MG/VIAL | TEFLARO | ABBVIE | N200327 | Oct. 29, 2010 | RX | POWDER | INTRAVENOUS | 8247400 | Feb. 10, 2031 | METHOD OF TREATING BACTERIAL INFECTIONS |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
ID | Source |
---|---|
4030298 | VUID |
N0000182256 | NUI |
D08884 | KEGG_DRUG |
400827-55-6 | SECONDARY_CAS_RN |
4030297 | VANDF |
4030298 | VANDF |
4030305 | VANDF |
C2001525 | UMLSCUI |
CHEBI:70718 | CHEBI |
1W8 | PDB_CHEM_ID |
CHEMBL3544973 | ChEMBL_ID |
CHEMBL501122 | ChEMBL_ID |
DB06590 | DRUGBANK_ID |
C515501 | MESH_SUPPLEMENTAL_RECORD_UI |
C490727 | MESH_SUPPLEMENTAL_RECORD_UI |
10899 | IUPHAR_LIGAND_ID |
8827 | INN_ID |
7P6FQA5D21 | UNII |
9852981 | PUBCHEM_CID |
1040004 | RXNORM |
177759 | MMSL |
27590 | MMSL |
d07706 | MMSL |
013547 | NDDF |
013548 | NDDF |
702414006 | SNOMEDCT_US |
702415007 | SNOMEDCT_US |
714785008 | SNOMEDCT_US |
C2001521 | UMLSCUI |
CHEMBL4594371 | ChEMBL_ID |
229016-73-3 | SECONDARY_CAS_RN |
189345-04-8 | SECONDARY_CAS_RN |
H36Z0FHR8K | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Teflaro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-0400 | POWDER, FOR SOLUTION | 400 mg | INTRAVENOUS | NDA | 27 sections |
Teflaro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-0400 | POWDER, FOR SOLUTION | 400 mg | INTRAVENOUS | NDA | 27 sections |
Teflaro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-0600 | POWDER, FOR SOLUTION | 600 mg | INTRAVENOUS | NDA | 27 sections |
Teflaro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-0600 | POWDER, FOR SOLUTION | 600 mg | INTRAVENOUS | NDA | 27 sections |